Phoenix Pharmalabs, Inc

Phoenix Pharmalabs, Inc is a privately held pre-clinical stage drug development company based in Utah. They are committed to providing effective pain therapy options without the risks of addiction and severe side effects. The company's lead candidate, PPL-138, boasts 100 times the potency of morphine for pain relief, with a low risk of abuse and no respiratory depression.

With a focus on addressing the opioid crisis, Phoenix Pharmalabs is advancing PPL-138 into Phase I human clinical trials by the end of 2023. Their second drug candidate, PPL-103, shows promise not only in pain treatment but also in addiction therapy, demonstrating low abuse potential and reduced opioid side effects. The company has raised over $23 million from various sources for drug development.

Phoenix Pharmalabs aims to capture a significant portion of the $30 billion opioid therapeutics market by offering innovative solutions to pain management. By developing drugs with unique opioid receptor characteristics that mitigate abuse and addiction risks, they seek strategic partnerships to further advance their drug candidates through pre-clinical and clinical trials.

Generated from the website content